OakChart

Kailera Therapeutics Inc

KLRAHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

14.38+0.14 (0.98%)
2026-11-12 05:40 CET
Market cap
1,867.24 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-95.67 USD m
Free cash flow, TTM
-133.67 USD m
EPS diluted, TTM
-0.74
P/E
-
Compare

Price

KLRA against its 20 and 50-day averages
2050beatearnings
10.0015.0020.0025.003.7M7.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26KLRAclose 14.3820-day 12.8550-day 12.6614.3852w low

49.1% under the 52-week high of 28.23 on 20 Apr 2026. 52-week low 9.76 on 8 Oct 2026. Last 15 sessions, 25.4% high to low

Volume 0.56× normal · the line is the 50-bar volume average

Profile

KLRA
52-week range, 25% of the way up
9.7628.23

Kailera Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Its product candidate includes Ribupatide. The company was founded on May 08, 2024 and is headquartered in Waltham, MA.

IndexRUT
Employees145
IPOApr 17, 2026
ATR, 14d0.99
Rel volume0.56
Short float14.37%
Insider own56.26%
Inst own44.82%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.87B
Enterprise Value975.77M
Income-
Sales-
Book/sh7.95
Cash/sh6.94
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees145
IPOApr 17, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.81
P/C2.07
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio21.84
Current Ratio21.84
Debt/Eq0.01
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-
EPS next Y-3.86
EPS next Q-0.90
EPS this Y-181.88%
EPS next Y1.44%
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y- -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-230.36%
Sales Q/Q-
EarningsNov 04 AMC
EPS/Sales Surpr.0.00% -

Ownership

Insider Own56.26%
Insider Trans0.00%
Inst Own44.82%
Inst Trans77.12%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2011.95%
SMA5013.55%
SMA200-18.79%
Trades-

Technical

Shs Outstand129.68M
Shs Float56.80M
Short Float14.37%
Short Ratio7.51
Short Interest8.16M
52W High28.23 -49.06%
52W Low9.76 47.34%
Volatility9.72% 7.48%
ATR (14)0.99
RSI (14)62.15
Beta-
Rel Volume0.56
Avg Volume1.09M
Volume610,327

Performance

Perf Week12.34%
Perf Month33.52%
Perf Quarter-19.98%
Perf Half Y-31.88%
Perf YTD-44.69%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price43.00
Prev Close14.24
Price14.38
Change %0.98%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
Nov 09, 2026InitiatedCCanaccord GenuityBuy$44+206.0%
May 12, 2026InitiatedWWilliam BlairOutperform
May 12, 2026InitiatedTTD CowenBuy$57+296.4%
May 12, 2026InitiatedLLeerink PartnersOutperform$36+150.3%
May 12, 2026InitiatedJJP MorganOverweight$30+108.6%
May 12, 2026InitiatedJJefferiesBuy$48+233.8%
May 12, 2026InitiatedEEvercore ISIOutperform

Peers

Mkt cap
TickerCompanyMkt cap
GPCRStructure Therapeutics Inc ADR1.49B
VKTXViking Therapeutics Inc3.63B
MBXMBX Biosciences Inc2.87B
ALTAltimmune Inc375.41M
SEPNSepterna Inc2.31B
LLYLilly(Eli) & Co1352.12B
NVONovo Nordisk ADR137.48B
WVEWave Life Sciences Inc674.52M
RYTMRhythm Pharmaceuticals Inc7.78B
AMGNAMGEN Inc253.21B

Insider trading

6 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Renaud Ronald C JRCEO & PresidentJun 09 '26Option Exercise5.2538,094199,99438,094Jun 11 04:05 PM
RTW INVESTMENTS, LP10% OwnerApr 20 '26Buy16.00500,0008,000,00010,776,820Apr 22 04:15 PM
BAIN CAPITAL INVESTORS LLC10% OwnerApr 20 '26Buy16.008,398,438134,375,00826,255,581Apr 20 06:10 PM
Koppel AdamDirectorApr 20 '26Buy16.001,562,50025,000,00022,583,268Apr 20 06:08 PM
Bain Capital Life Sciences Inv10% OwnerApr 20 '26Buy16.001,562,50025,000,00022,583,268Apr 20 06:01 PM
Kaplan Andrew T.DirectorApr 20 '26Buy16.008,398,438134,375,00826,255,581Apr 20 06:00 PM

Held by

AUM
TickerCompanyAUM
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
OZEMRoundhill GLP-1 & Weight Loss ETFAUM: 58.23M
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B

News

latest 14 of 48
  • Kailera Therapeutics to Present at ObesityWeek 2026 (GlobeNewswire)
  • Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
  • Kailera Therapeutics to Participate in November Investor Conferences (GlobeNewswire)
  • How to Invest in the Rise of China's Biotech: Buy U.S. Drug Stocks (Barrons.com)
  • Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting (GlobeNewswire)
  • Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection (GlobeNewswire)
  • Kailera Therapeutics to Participate in September Investor Conferences (GlobeNewswire) -5.58%
  • Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
  • Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer (GlobeNewswire)
  • Kailera weight loss pill trial results: Nausea sinks stock (Quartz)
  • Eli Lilly's Market Cap Balloons Again On This IPO's Setback (Investor's Business Daily)
  • Kailera says obesity pill succeeds in late-stage trial in China (BioPharma Dive)
  • Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535 (GlobeNewswire)
  • Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.734-0.734-0.7730.000.005
2026Q22026-08-12-1.090-0.897-0.8590.000.006
2026Q12026-05-26-3,650-0.775-0.6090.000.004
2026Q4---0.903--0.006
2027Q1---0.891--0.003
2027Q2---1.027--0.003
2027Q3---1.092--0.003
2027Q4---1.120--0.003
2028Q1---1.166---1
2028Q2---1.154---1
2028Q3---1.308---1
2028Q4---1.411---1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY-1.390--0.9500.00-
2026FY--3.918--0.00
2027FY--3.862--0.00
2028FY--3.881--0.00
2029FY--4.303--66.90
2030FY--3.099--443.4

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-055000.000.000.00
2026Q4S2026-10-015000.000.000.00
2026Q4S2026-08-194000.000.000.00
2026Q4S2026-08-135000.000.000.00
2026Q4S2026-05-275000.000.000.00
2026Q4S2026-05-114000.000.000.00
2026Q4S2026-05-081000.000.000.00
2026Q4R2026-11-05311-0.92-0.95-0.90
2026Q4R2026-11-04310-0.90-0.95-0.83
2026Q4R2026-10-27300-0.93-1.01-0.83
2026Q4R2026-10-01311-0.93-1.01-0.83
2026Q4R2026-08-19211-0.92-1.01-0.83
2026Q4R2026-08-13311-0.93-1.01-0.83
2026Q4R2026-08-10300-1.01-1.09-0.95

Estimate history

EPS, annual-2.597-1.76
Period20242025
EPS, quarterly-0.223-0.306-0.609-0.859-0.738
PeriodQ2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Sales, annual00
Period20242025
Sales, quarterly00000
PeriodQ2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Shares, annual84.61584.615129.684
Period20242025MRQ
Shares, quarterly129.62129.566129.566129.62129.684
PeriodQ2 '25Q3 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY
Total Revenue0.000.000.00
Cost of Goods Sold Incl. D&A0.100.310.05
Gross Profit-0.10-0.31-0.05
Selling, General and Administrative Excl. Other106.23158.0316.29
Research and Development84.67109.116.97
Other Operating Expense0.000.000.00
Operating Income-106.34-158.34-16.35
Interest Expense0.00-0.00
Unusual Expense0.001.66205.88
Net Income Before Taxes-95.67-148.96-219.71
Income Taxes0.000.000.00
Consolidated Net Income-95.67-148.96-219.71
Net Income From Continuing Operations-95.67-148.96-219.71
Net Income-95.67-148.96-219.71
EPS (Recurring)-0.74-1.75-0.89
EPS (Basic, Before Extraordinaries)-0.74-1.76-2.60
EPS (Diluted)-0.74-1.76-2.60
EBITDA-106.23-158.03-16.29
Non-Operating Income (Expense)10.6711.052.51
Other After Tax Adjustments0.000.000.00
Stock Option Compensation Expense9.9210.940.94
Shares Outstanding129.6884.6284.62
Market Capitalization1,867.241,867.24-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q2
Total Revenue0.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.100.100.100.060.06
Gross Profit-0.10-0.10-0.10-0.06-0.06
Selling, General and Administrative Excl. Other106.23121.2784.5640.0530.59
Research and Development84.67101.0670.8726.9919.52
Other Operating Expense0.000.000.000.000.00
Operating Income-106.34-121.37-84.66-40.11-30.65
Interest Expense0.000.000.000.000.00
Unusual Expense0.000.000.000.000.00
Net Income Before Taxes-95.67-111.31-78.86-39.62-28.95
Income Taxes0.000.000.000.000.00
Consolidated Net Income-95.67-111.31-78.86-39.62-28.95
Net Income From Continuing Operations-95.67-111.31-78.86-39.62-28.95
Net Income-95.67-111.31-78.86-39.62-28.95
EPS (Recurring)-0.74-0.86-0.61-0.31-0.22
EPS (Basic, Before Extraordinaries)-0.74-0.86-0.61-0.31-0.22
EPS (Diluted)-0.74-0.86-0.61-0.31-0.22
EBITDA-106.23-121.27-84.56-40.05-30.59
Non-Operating Income (Expense)10.6710.075.790.491.70
Other After Tax Adjustments0.000.000.000.000.00
Stock Option Compensation Expense9.922.433.944.270.28
Shares Outstanding129.68129.62129.57129.57129.62
Market Capitalization1,867.242,854.342,807.70--

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY
Cash & Short Term Investments546.06175.18
Short Term Receivables2.730.00
Inventories0.000.00
Other Current Assets8.762.43
Total Current Assets557.54177.61
Net Property, Plant & Equipment12.420.68
Total Investments and Advances107.430.00
Intangible Assets-0.00
Deferred Tax Assets0.12-
Other Assets14.910.15
Total Assets692.41178.44
Short Term Debt Incl. Current Port. of LT Debt1.040.51
Accounts Payable7.532.01
Other Current Liabilities37.844.39
Total Current Liabilities46.416.91
Long Term Debt9.710.00
Provision for Risks Charges0.000.00
Deferred Tax Liabilities0.12-
Other Liabilities0.270.00
Total Liabilities56.516.91
Non-Equity Reserves0.000.00
Preferred Stock - Carrying Value992.36390.31
Common Equity-356.46-218.77
Total Shareholders Equity635.91171.53
Accumulated Minority Interest0.000.00
Total Equity635.91171.53
Total Liabilities & Stockholders Equity692.41178.44
Book Value Per Share-4.21-2.59
Tangible Book Value Per Share-4.21-2.59
Full-Time Employees145-
Price to Book Ratio1.81-
Return on Assets-34.21-
Return on Equity-36.90-
Return on Invested Capital-23.07-128.09
Quick Ratio12.0125.70
Current Ratio12.0125.70

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY
Net Income-95.67-148.96-219.71
Depreciation0.100.310.05
Other Funds (Non Cash)7.8311.6593.94
Funds from Operations-87.73-136.99-125.72
Extraordinary Item0.000.000.00
Changes in Working Capital-45.9416.782.42
Cash from Operating Activities-133.67-120.21-123.30
Capital Expenditures0.00-2.09-0.26
Net Assets From Acquisitions0.000.000.00
Sale of Fixed Assets and Businesses0.000.000.00
Purchase or Sale of Investments110.83-490.510.00
Purchase of Investments-37.06-632.160.00
Sale Or Maturity of Investments147.89141.650.00
Other Uses0.000.000.00
Other Sources0.000.000.00
Cash from Investing Activities110.83-492.60-0.26
Cash Dividends Paid0.000.000.00
Preferred Dividends (Cash Flow)0.000.000.00
Change in Capital Stock-0.92498.66298.74
Repurchase of Common Pref Stock0.000.000.00
Sale of Common Pref Stock-0.92498.66298.74
Proceedsfrom Stock Options-1.26498.56298.74
Issuance or Reduction of Debt, Net0.00100.000.00
Change in Long Term Debt0.000.000.00
Issuance of Long Term Debt0.000.000.00
Reduction of Long Term Debt0.000.000.00
Net Financing Active Other Cash Flow0.000.000.00
Other Financing Activities Uses0.000.000.00
Cash from Financing Activities-0.92598.66298.74
Net Change in Cash-23.76-14.15175.18
Free Cash Flow-133.67-122.30-123.56
Deferred Taxes & Investment Tax Credit-0.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q2
Cash & Short Term Investments901.45916.74519.17--
Short Term Receivables6.266.113.21--
Inventories0.000.000.00--
Other Current Assets12.046.317.93--
Total Current Assets919.76929.17530.32--
Net Property, Plant & Equipment11.2811.6512.02--
Total Investments and Advances136.95255.8463.51--
Other Assets14.1914.7618.91--
Total Assets1,082.181,211.42624.76--
Short Term Debt Incl. Current Port. of LT Debt1.091.051.03--
Accounts Payable9.4319.207.09--
Other Current Liabilities31.5963.4046.71--
Total Current Liabilities42.1283.6554.84--
Long Term Debt8.889.179.44--
Provision for Risks Charges0.000.000.00--
Other Liabilities0.070.140.20--
Total Liabilities51.0692.9564.48--
Non-Equity Reserves0.000.000.00--
Preferred Stock - Carrying Value0.000.00992.36--
Common Equity1,031.121,118.46-432.09--
Total Shareholders Equity1,031.121,118.46560.28--
Accumulated Minority Interest0.000.000.00--
Total Equity1,031.121,118.46560.28--
Total Liabilities & Stockholders Equity1,082.181,211.42624.76--
Book Value Per Share7.958.63-3.33--
Tangible Book Value Per Share7.958.63-3.33--
Price to Book Ratio1.81-6.61-6.50--
Return on Invested Capital-9.20-9.87-13.84--
Quick Ratio21.8411.119.67--
Current Ratio21.8411.119.67--

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q2
Net Income-95.67-111.31-78.86-39.62-
Depreciation0.100.100.100.06-
Other Funds (Non Cash)7.836.962.996.01-
Funds from Operations-87.73-104.25-75.78-33.55-
Extraordinary Item0.000.000.000.00-
Changes in Working Capital-45.9426.727.473.85-
Cash from Operating Activities-133.67-77.53-68.31-29.70-
Capital Expenditures0.000.000.00-0.44-
Net Assets From Acquisitions0.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.00-
Purchase or Sale of Investments110.83-571.0222.8526.93-
Purchase of Investments-37.06-689.81-48.45-42.28-
Sale Or Maturity of Investments147.89118.7971.3069.20-
Other Uses0.000.000.000.00-
Other Sources0.000.000.000.00-
Cash from Investing Activities110.83-571.0222.8526.48-
Cash Dividends Paid0.000.000.000.00-
Preferred Dividends (Cash Flow)0.000.000.000.00-
Change in Capital Stock-0.92667.03-2.98-0.24-
Repurchase of Common Pref Stock0.000.000.000.00-
Sale of Common Pref Stock-0.92667.03-2.98-0.24-
Proceedsfrom Stock Options-1.26666.60-3.04-0.24-
Issuance or Reduction of Debt, Net0.000.000.000.00-
Change in Long Term Debt0.000.000.000.00-
Issuance of Long Term Debt0.000.000.000.00-
Reduction of Long Term Debt0.000.000.000.00-
Net Financing Active Other Cash Flow0.000.000.000.00-
Other Financing Activities Uses0.000.000.000.00-
Cash from Financing Activities-0.92667.03-2.98-0.24-
Net Change in Cash-23.7618.48-48.44-3.46-
Free Cash Flow-133.67-77.53-68.31-30.14-

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3014.37%8.2M56.8M1.02M
2026-10-1514.66%8.3M56.7M929.54K
2026-09-3015.31%8.7M56.7M798.97K
2026-09-1510.51%6.0M56.7M805.64K
2026-08-319.98%5.7M56.7M746.74K
2026-08-1410.70%6.1M56.7M671.47K
2026-07-317.42%6.6M89.3M694.37K
2026-07-157.18%6.4M89.3M929.91K
2026-06-305.71%5.1M89.3M973.83K
2026-06-152.91%2.6M89.3M800.44K
2026-05-293.01%2.7M89.4M928.43K
2026-05-152.97%2.7M89.3M1.15M
2026-04-302.24%2.0M87.4M1.91M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.509.5014.000.0023.3830.000.000.992-0.0170.001
call5.007.0011.500.0011.5310.000.000.985-0.0170.001
call7.504.509.000.007.7440.000.000.977-0.0170.001
call10.002.006.502.935.3950.000.000.942-0.0250.003
call12.500.104.901.604.76915.000.000.888-0.0200.004
call15.000.253.500.604.23929.000.000.604-0.2060.009
call17.500.002.950.003.9690.000.000.497-0.2000.009
call20.000.002.950.155.1221.000.000.495-0.2590.009
call22.500.002.950.005.6500.000.000.474-0.2850.009
put2.500.002.950.005.8050.000.00-0.008-0.0170.001
put5.000.002.950.004.9140.000.00-0.040-0.0530.002
put7.500.000.050.053.23430.000.00-0.063-0.0500.003
put10.000.000.250.601.9391.000.00-0.101-0.0410.004
put12.500.000.100.851.8481230.00-0.270-0.0760.007
put15.000.004.000.004.0670.000.00-0.397-0.2020.009
put17.501.005.500.003.8570.000.00-0.473-0.2240.009
put20.003.508.000.004.5150.000.00-0.505-0.2570.009
put22.506.0010.500.005.0440.000.00-0.526-0.2830.009

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-07SEC
2026-09-093Initial statement of beneficial ownership of securities2026-08-31SEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13GSEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-08-05SCHEDULE 13GSEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-07-083Initial statement of beneficial ownership of securities2026-06-29SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-05-2610-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-268-KCurrent report2026-05-26SEC
2026-04-23SCHEDULE 13DSEC
2026-04-23SCHEDULE 13DSEC
2026-04-224Statement of changes in beneficial ownership of securities2026-04-20SEC
2026-04-224Statement of changes in beneficial ownership of securities2026-04-20SEC
2026-04-204Statement of changes in beneficial ownership of securities2026-04-20SEC
2026-04-204Statement of changes in beneficial ownership of securities2026-04-16SEC
2026-04-204Statement of changes in beneficial ownership of securities2026-04-20SEC
2026-04-204Statement of changes in beneficial ownership of securities2026-04-16SEC
2026-04-204Statement of changes in beneficial ownership of securities2026-04-16SEC
2026-04-204Statement of changes in beneficial ownership of securities2026-04-16SEC
2026-04-204Statement of changes in beneficial ownership of securities2026-04-16SEC
2026-04-204Statement of changes in beneficial ownership of securities2026-04-16SEC
2026-04-204Statement of changes in beneficial ownership of securities2026-04-16SEC
2026-04-204Statement of changes in beneficial ownership of securities2026-04-16SEC
2026-04-204Statement of changes in beneficial ownership of securities2026-04-16SEC
2026-04-204Statement of changes in beneficial ownership of securities2026-04-16SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-04326.75M500
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BAIN CAPITAL INVESTORS LLC20.26%
Bain Capital Life Sciences Investors, LLC17.43%
RTW INVESTMENTS, LP8.32%
CANADA PENSION PLAN INVESTMENT BOARD5.64%
Atlas Venture Life Science Advisors, LLC3.99%
FMR LLC3.59%
BlackRock, Inc.3.03%
PRICE T ROWE ASSOCIATES INC /MD/2.73%
CITADEL ADVISORS LLC2.50%
ADAGE CAPITAL PARTNERS GP, L.L.C.2.48%

Funds

Fund% owned
VANGUARD HEALTH CARE FUND1.69%
VANGUARD TOTAL STOCK MARKET INDEX FUND0.91%
iShares Russell 2000 ETF0.90%
T. Rowe Price Health Sciences Fund, Inc.0.70%
VANGUARD SMALL-CAP INDEX FUND0.66%
Columbia Small Cap Growth Fund0.60%
Fidelity Growth Company Fund0.54%
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund0.49%
Select Biotechnology Portfolio0.49%
Eventide Healthcare & Life Sciences Fund0.48%

OakChart. KLRA. Cached 15 minutes.